ARTICLE | Tools & Techniques
Flexible platform: how NCI’s Sharpless thinks COVID variants could boost personalized therapies
Platform-based vaccine regulation could answer questions for cancer neoantigens and rare diseases
March 5, 2021 8:11 PM UTC
As regulators embrace platform technologies to rapidly update COVID-19 vaccines, they are laying the groundwork for personalized cancer and rare disease therapies, according to NCI Director Ned Sharpless.
FDA’s lack of regulatory frameworks for n-of-one medicines was one of Sharpless’ major take-homes from his seven-month stint as acting FDA commissioner between April and November in 2019. Sharpless has since returned to his role leading NIH’s National Cancer Institute, which he has held since 2017...
BCIQ Company Profiles